The Emmes Corporation today announced its statistical and data management support of a clinical trial that offers new hope for children with cerebral palsy (CP). Stephen Wease and Dr. Beth Blackwell joined a team of prominent researchers from Duke University Medical Center to test whether umbilical cord blood would improve motor skills function in children suffering from the disorder.
According to Wease, Emmes project leader, “The phase II trial showed promising results, and we’re eager for the next phases of research to further our understanding of this encouraging new mechanism for treating children with CP.”
The Emmes Corporation today announced that it was named one of the top women-owned businesses in the Washington metropolitan area by the Washington Business Journal. The company was ranked as the seventh largest women-owned business in the Washington region, up from number eight last year.
Emmes was also included as one of the Washington Business Journal’s Top 100 private companies in September. Last year’s revenues were $90 million, and the company now has more than 600 employees.
The Emmes Corporation today announced that Dr. Paul VanVeldhuisen, chief operating officer and principal investigator, co-authored a study published by the Journal of the American Medical Association (JAMA). The study focused on the efficacy and safety of a commonly used, off-label drug called Avastin in treating macular edema due to central retinal vein occlusion. The study also addressed how Avastin compared to another drug, Eylea, which has been approved by the FDA and is being used to treat the same disease.
The 2-1/2-year study with nearly 400 patients concluded that Avastin was as effective as Eylea in improving vision after six months of treatment. The cost of Avastin is $60 per dose compared to Eylea’s $1,850 per dose.
The Emmes Corporation today announced a contract spanning just over four years for a Phase 2 study of a Zika vaccine. The contract, valued at up to $27.6 million, expands the initial Phase 1 testing that began last year. This is the first-ever Phase 2 study for a Zika vaccine.
Dr. Anne Lindblad, president and chief executive officer of Emmes, said, “The win is important because it expands our role in combating the Zika virus, a significant and enduring public health challenge.”
The Emmes Corporation today announced the highest revenues in its 40‐year history along with significant growth in its employee count. Revenues surpassed $90 million in 2016, and it employed 567 employees in its U.S. and international offices.